InspireMD(NSPR)2025-03-12 11:43Revenue and Profit - Total revenue for Q4 2024 increased by 1,949,000 compared to 804,000, or 13.0%, to 6,205,000 in 2023[10] - Gross profit for Q4 2024 decreased by 469,000, with a gross margin of 24.1%[5][22] - Gross profit for the full year 2024 decreased by 1,506,000, with a gross margin of 21.5%[11][12] Operating Expenses and Loss - Total operating expenses for Q4 2024 were 3,523,000, or 55.8%, compared to 35,009,000, an increase of 22,950,000 in 2023[13] - Net loss for Q4 2024 totaled 0.19 per share, compared to a net loss of 0.16 per share, in Q4 2023[8][22] - Net loss for the full year 2024 totaled 0.76 per share, compared to a net loss of 0.82 per share, in 2023[15][22] Cash and Securities - Cash and cash equivalents and marketable securities as of December 31, 2024, were 39,023,000 as of December 31, 2023[9] Liabilities and Equity - Total current liabilities increased to 6,020 million in 2023, representing a 27.5% increase[25] - Total long-term liabilities rose to 2,122 million in 2023, marking a 43.4% increase[25] - Total liabilities reached 8,142 million in 2023, reflecting a 31.7% increase[25] - Total equity decreased to 39,501 million in 2023, a decline of 8.9%[25] - Additional paid-in capital increased to 261,000 million in 2023, showing an increase of 11%[25] - The accumulated deficit widened to (221,501) million in 2023, indicating a deterioration of 14.5%[25] - The number of common shares issued and outstanding increased to 26,611,033 in 2024 from 21,841,215 in 2023, a growth of 21.9%[25] - Total liabilities and equity amounted to 47,643 million in 2023, a decrease of 1.8%[25] Lease and Employee Liabilities - Operating lease liabilities increased to 1,038 million in 2023, representing a 73.2% increase[25] - Liability for employee rights upon retirement and others rose to 1,084 million in 2023, a 15.1% increase[25] Future Prospects - The company anticipates a potential U.S. launch of the CGuard Prime carotid stent system in the first half of 2025, pending FDA approval[3][6]